Partner Headlines - ARNA

  1. Earnings Scheduled For August 1, 2014

    Benzinga
  2. Benzinga's Top #PreMarket Losers

    Benzinga
  3. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  4. Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His ...

    Benzinga
  5. Benzinga's Top #PreMarket Losers

    Benzinga
  6. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  7. FDA delays Orexigen drug

    IBD
  8. Is Arena Pharmaceuticals A Biotech Stock To Watch?

    Benzinga
  9. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  10. Orexigen Shares Plummet Following FDA Decision; Competition Gets ...

    Benzinga
  11. Arena Pharma Posts Q1 Loss Of $0.12/Share, Misses By ~$0.02/Share

    Benzinga
  12. Earnings Scheduled For May 12, 2014

    Benzinga
  13. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  14. Benzinga's Top #PreMarket Losers

    Benzinga
  15. Earnings Scheduled For February 27, 2014

    Benzinga
  16. Bad Earnings Weigh In On Diet Stocks

    Benzinga
  17. Top Trending Tickers On StockTwits For February 14

    Benzinga
  18. #PreMarket Primer: Friday, February 14: A Turnaround

    Benzinga
  19. Arena Pharmaceuticals Announces Filing for Marketing Authorization ...

    Benzinga
  20. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
  21. The Top Five Drug Launches Of 2013

    IBD
  22. (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance ...

    GuruFocus
  23. Benzinga's Top #PreMarket Gainers

    Benzinga
  24. Market Wrap For November 11: Relative Quiet as Traders and Investors ...

    Benzinga
  25. Market Wrap For November 8: Markets Erase Thursday's Losses; ...

    Benzinga
  26. Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement ...

    Benzinga
  27. Nasdaq Leads Stocks Lower; Twitter IPO Opens To 80% Gain

    IBD
  28. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  29. Benzinga's Top #PreMarket Losers

    Benzinga
  30. Market Wrap For Tuesday, October 15: Earnings Reports And White ...

    Benzinga
  31. Mid-Afternoon Market Update: Tumi Holdings Rises Amid Market ...

    Benzinga
  32. Mid-Morning Market Update: Markets Slip; Citigroup Profit Misses ...

    Benzinga
  33. UPDATE: Arena Says Eisai Will Double BELVIQ Sales Force to 4 ...

    Benzinga
  34. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and ...

    Benzinga
  35. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  36. Benzinga's Top Pre-Market Losers

    Benzinga
  37. Market Wrap For September 30: Debt Ceiling And Government Shutdown ...

    Benzinga
  38. Mid-Afternoon Market Update: Mellanox Rallies As Market Remains ...

    Benzinga
  39. Mid-Day Market Update: Dow Falls Over 100 Points; Active Network ...

    Benzinga
  40. Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net ...

    Benzinga
  41. UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following ...

    Benzinga
  42. Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing ...

    Benzinga
  43. Stocks Hitting 52-Week Lows

    Benzinga
  44. BMO Considers Recent Sales Data on Arena's Belviq, Maintains ...

    Benzinga
  45. CEO Shift Aside, Whose Weight-Loss Pill’s Ahead

    YCharts
  46. Stocks Hitting 52-Week Lows

    Benzinga
  47. Stocks Hitting 52-Week Lows

    Benzinga
  48. Arena Pharma Reports Closing of Phase 1b Clinical Trial for APD811

    Benzinga
  49. Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, ...

    Benzinga
  50. It's Hard to Sell a Pill That Nobody's Heard Of

    YCharts
  51. Weekly Preview: Earnings Season Continues, Fed In Focus, Economic ...

    Benzinga
  52. Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

    Benzinga
  53. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga
  54. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga
  55. Mid-Afternoon Market Update: Markets All Green, Research in Motion ...

    Benzinga
  56. Mid-Day Market Update: GenCorp Rises, Markets Erasing Losses

    Benzinga
  57. Mid-Morning Market Update: Verizon Misses Big on Earnings, Research ...

    Benzinga
  58. Vivus fell 4.2% to 13.72

    IBD
  59. Vivus Stock Drops On Downgrade; Rival Arena Rises

    IBD
  60. Measuring Social Network Buzz Over Pharma Stocks

    YCharts
  61. Vivus Stock Jumps On Latest Qsymia Shipment Numbers

    IBD
  62. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga
  63. Benzinga's Top Pre-Market Gainers

    Benzinga
  64. The Best Small Cap Performers of 2012

    Benzinga
  65. Vivus Soars On Qsymia Anti-Obesity Drug Prescriptions

    IBD
  66. Acadia Pharma Rockets Higher on Study Results

    Benzinga
  67. Vivus Stock Soars As Aetna Adds Qsymia To Coverage

    IBD
  68. Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

    Benzinga
  69. Arena Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  70. UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT ...

    Benzinga
  71. Vivus Earnings Miss Estimates; Arena Waits In Wings

    IBD
  72. Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

    Benzinga
  73. Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical ...

    Benzinga
  74. WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC

    GuruFocus
  75. Who Needs Diet and Exercise? Health Plans Cover New Vivus Obesity ...

    YCharts
  76. Vivus Expects EU To Reject Diet Drug, Shares Fall

    IBD
  77. Vivus Dives 11% After Warning EU May Not Back Obesity Drug

    FoxBusiness
  78. Stocks Finish Little Changed with Yahoo (YHOO) and FedEx (FDX) ...

    MarketIntelligenceCenter
  79. All Eyes On Vivus As Weight Loss Drug Hits Market

    YCharts
  80. Short Sellers Shy Away from Biotech Firms

    Benzinga
  81. Benzinga's Top Pre-Market Gainers

    Benzinga
  82. UPDATE: Credit Suisse Initiates Arena Pharmaceuticals at Underperform ...

    Benzinga
  83. Health Care Sector Wrap

    FoxBusiness
  84. Short Interest in Biotech Firms on the Rise

    Benzinga
  85. What Slims Down Fastest After Diet Drugs Are Approved by he FDA? ...

    YCharts
  86. Health Care Sector Wrap

    FoxBusiness
  87. Arena Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  88. Four Investment Options Presented by Obesity and Related Health ...

    YCharts
  89. Biotechs In Motion As New Drug Pipeline Brims

    IBD
  90. Who's Next Facebook? VCs Try Software, Internet Firms

    IBD
  91. Arena Pharmaceuticals (ARNA) Falls 8.3% After Rival Weight Loss ...

    MarketIntelligenceCenter
  92. Wednesday Market Movers

    Benzinga
  93. Vivus Stock Jumps 12.5% On Drug Approval

    IBD
  94. Benzinga's Top Pre-Market Losers

    Benzinga
  95. Drug Stocks Up On Glaxo, Par M&A And Gilead HIV Pill

    IBD
  96. Vivus Rises Ahead Of FDA Vote On Qnexa Diet Drug

    IBD
  97. Stocks Move Lower as Euro Zone and Earnings Worries Persist with ...

    MarketIntelligenceCenter
  98. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
  99. Benzinga's Top Pre-Market Gainers

    Benzinga
  100. Arena Pharmaceuticals Inc. (ARNA) SVP, Finance and CFO Robert ...

    GuruFocus
Trading Center